Mural Oncology plc
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Caroline J. Loew
- Full Time Employees
- 116
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 10 Earlsfort Terrace Dublin Ireland D02 T380
- IPO Date
- Nov 16, 2023
- CIK
- 0001971543
- Website
- muraloncology.com
- Similar Companies
- Business
- Mural Oncology plc (Nasdaq: MURA) is a clinical-stage immuno-oncology company that leverages protein engineering and expertise in cytokine biology and immune cell modulation to develop novel engineered cytokine immunotherapies targeting difficult-to-treat cancers with high unmet need, including tumors unresponsive to checkpoint inhibitors; its lead product candidate, nemvaleukin alfa, an engineered interleukin-2 (IL-2) cytokine designed to deliver therapeutic benefits of high-dose recombinant human IL-2 while reducing associated toxicities, is in potentially registrational phase 3 trials (ARTISTRY-7 in combination with pembrolizumab for platinum-resistant ovarian cancer and ARTISTRY-6 as monotherapy for mucosal melanoma), phase 2 ARTISTRY-3 trial for less-frequent intravenous dosing in advanced solid tumors including cutaneous melanoma, and additional studies in advanced solid tumors; the company advances preclinical programs in engineered interleukin-18 (MURA-8518, with investigational new drug submission planned for Q4 2025) and tumor-targeted interleukin-12 (MURA-7012, with preferential self-assembly at tumor sites to minimize systemic exposure). Founded in 2017 and headquartered in Dublin, Ireland, with primary facilities in Waltham, Massachusetts, Mural Oncology operates globally in the biotechnology sector, focusing on oncology patients across diverse tumor types such as ovarian cancer, mucosal and cutaneous melanoma, and advanced solid tumors, with clinical trials enrolling in multiple countries. In recent developments, the company nominated two new development candidates, MURA-8518 (IL-18) and MURA-7012 (IL-12), in early 2025, reached 75% of overall survival events in the ARTISTRY-7 trial with interim data anticipated in late Q1/early Q2 2025 and top-line results from ARTISTRY-6 Cohort 2 expected in Q2 2025, extended its cash runway into Q1 2026, announced plans to explore strategic alternatives in April 2025, and entered into a definitive agreement in August 2025 to be acquired by XOMA Royalty Corporation through a wholly-owned subsidiary via a scheme of arrangement under Irish law, with final cash consideration set at $2.035 per share, Irish High Court approval received on December 3, 2025, and closing expected on December 5, 2025.
Mural Oncology PLC (NASDAQ:MURA) Receives $12.00 Consensus PT from Brokerages
Mural Oncology PLC (NASDAQ:MURA) Receives $12.00 Consensus Price Target from Brokerages
XOMA Royalty Announces Closing of Transaction to Acquire Mural Oncology plc
Mural Oncology Announces Effectiveness of Scheme of Arrangement and Completion of Acquisition
Mural Oncology Announces Sanction of the Scheme by the High Court
Mural Oncology Announces Final Cash Consideration Payable on Closing of Acquisition by XOMA Royalty
Mural Oncology Announces that Mural Shareholders Approve the Proposed Acquisition by XRA 5 Corp., a Wholly Owned Subsidiary of XOMA Royalty
Mural Oncology Announces Commencement of Mailing of Definitive Proxy Statement and Details of Scheme Meeting and Extraordinary General Meeting
SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Mural Oncology plc (NASDAQ: MURA)
MURA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Mural Oncology plc Is Fair to Shareholders
Mural Oncology Announces Entry into Agreement to be Acquired by XRA 5 Corp., a wholly owned subsidiary of XOMA Royalty for between $2.035 and $2.24 in Cash per Share
Mural Oncology (MURA) Q2 Loss Widens 49%
Mural Oncology Announces Second Quarter Financial Results and Provides Business Update
Mural Oncology Announces Number of Relevant Securities in Issue
FORM 8.1(a) & (b) - Mural Oncology plc
MURA Soars as it Explores Strategic Options Post Cancer Study Failures
Mural Oncology Announces Plans to Explore Strategic Alternatives
Mural Oncology's Ovarian Cancer Combo Drug Trial Disappoints, Stock Plunges
Mural Oncology Provides Update on Phase 3 ARTISTRY-7 Trial of Nemvaleukin in Combination with KEYTRUDA® (pembrolizumab) in Patients with Platinum-Resistant Ovarian Cancer
Mural Oncology Announces Fourth Quarter and Year End 2024 Financial Results and Highlights Upcoming Clinical Milestones